Table 2 Therapeutics data and evolution during ICU stay of patients with severe pneumococcal pneumonia*
From: Severe pneumococcal pneumonia: impact of new quinolones on prognosis
Characteristics | Overall population n = 70 | Group A n = 38 | Group B n = 32 | P |
|---|---|---|---|---|
Cephalosporin in initial treatment | 46 (65.7%) | 20 (52.6%) | 26 (81.3%) | 0.01 |
Use of drotrecogin alpha | 4 (5.7%) | 0 | 4 (12.5%) | 0.02 |
Intensive insulin therapy | 30 (42.8%) | 4 (10.5%) | 26 (81.2%) | <0.0001 |
Use of hydrocortisone | 24 (34.3%) | 6 (15.7%) | 18 (56.3%) | 0.0004 |
Haemodialysis | 10 (14.3%) | 3 (7.8%) | 7 (21.8%) | 0.09 |
Body temperature on D3 | 37.4 ± 1.3 | 37.8 ± 1.0 | 36.9 ± 1.3 | 0.0008 |
SOFA score on D3 | 7.5 ± 4.8 | 8.0 ± 5.1 | 7.1 ± 4.5 | 0.48 |
Improvement on D3 | 43 (61.4%) | 20 (52.6%) | 23 (71.8%) | 0.09 |
Body temperature on D5 | 37.5 ± 0.9 | 37.7 ± 0.9 | 37.3 ± 0.9 | 0.22 |
SOFA score on D5 | 6.4 ± 4.8 | 7.5 ± 4.9 | 5.5 ± 4.5 | 0.13 |
Body temperature on D7 | 37.4 ± 1.0 | 37.7 ± 0.9 | 37.0 ± 1.0 | 0.04 |
SOFA score on D7 | 6.6 ± 5.0 | 7.7 ± 5.0 | 5.6 ± 4.8 | 0.17 |
Sepsis-related complications | 31 (44.3%) | 16 (42.1%) | 15 (46.8%) | 0.68 |
HA-LRT superinfections | 17 (24.3%) | 7 (18.4%) | 10 (31.2%) | 0.21 |
ICU-related complications | 12 (17.1%) | 8 (21.0%) | 4 (12.5%) | 0.34 |
Duration of MV (days) | 11.3 ± 14.3 | 11.2 ± 15.6 | 11.5 ± 12.9 | 0.93 |
Duration of vasopressor use (days) | 3.5 ± 4.8 | 3.6 ± 5.6 | 3.3 ± 3.9 | 0.80 |
LOS in ICU (days) | 14.6 ± 16.3 | 14.5 ± 19.0 | 14.6 ± 12.6 | 0.97 |
Mortality on D-15 | 14 (20%) | 12 (31.6%) | 2 (6.3%) | 0.02 |
Mortality in ICU | 26 (37.1%) | 17 (44.8%) | 9 (28.1%) | 0.15 |